[SCHEDULE 13D/A] Biomea Fusion, Inc. SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

SCHEDULE 13D/A

Rhea-AI Filing Summary

Analyzing...

07/22/2025 - 05:15 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Biomea Fusion, Inc.

NASDAQ:BMEA

BMEA Rankings

#6654 Ranked by Market Cap

N/A Ranked by Dividends

BMEA Latest News

Jun 23, 2025

Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

Jun 17, 2025

Biomea Fusion Announces Pricing of Public Offering of Securities

Jun 17, 2025

Biomea Fusion Announces Proposed Public Offering of Securities

Jun 13, 2025

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

BMEA Latest SEC Filings

Jul 16, 2025

[SCHEDULE 13G/A] Biomea Fusion, Inc. SEC Filing

Jun 25, 2025

[SCHEDULE 13G] Biomea Fusion, Inc. SEC Filing

Jun 20, 2025

[8-K] Biomea Fusion, Inc. Reports Material Event

Jun 18, 2025

[424B5] Biomea Fusion, Inc. Prospectus Supplement (Debt Securities)

Jun 18, 2025

[8-K] Biomea Fusion, Inc. Reports Material Event

BMEA Stock Data

Market Cap 101.50M

Float 51.46M

Insiders Ownership 25.02%

Institutions Ownership 63.55%

Short Percent 30.62%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City REDWOOD CITY